Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir

Objectives To investigate the association between the UGT1A1*6 (G71R) and UGT1A1*28 (promoter (TA)7-repeat) genotypes and hyperbilirubinaemia in Thai patients treated with indinavir, and characterize the inhibition of human UGTs by indinavir in vitro. Methods Ninety-six Thai HIV patients receiving indinavir, 800 mg t.i.d. or 800 mg b.i.d. ‘boosted’ with ritonavir (100 mg b.i.d.), had serum bilirubin levels measured to 24 weeks post-treatment and were genotyped for UGT1A1*6 and UGT1A1*28. The inhibition selectivity and kinetics of indinavir were determined using a panel of recombinant human UGTs. Results UGT1A1*6 and UGT1A1*28 frequencies in the Thai patients were 10.4% and 15.6%, respectively. Total, conjugated (direct) and unconjugated (indirect) serum bilirubin concentrations increased significantly at 24 weeks of indinavir treatment for all four genotypes, with a trend towards higher levels depending on the number of UGT1A1 mutant alleles; *6/*28 > *6 > *28 > reference. The hazards ratio (HR) for serious hyperbilirubinaemia (total bilirubin > 2.5 mg/dl) at week 24 was statistically significant only in those patients carrying the UGT1A1*6 (HR 2.87) and UGT1A1*6/*28 (HR 11.42) genotypes. The Ki values for indinavir inhibition of UGT1A1 and UGT1A1*6 were 4.1 and 10.7 μmol/l respectively. However, indinavir was also shown to inhibit other human UGTs, notably UGT1A3 and UGT1A7. Conclusions In contrast to Caucasian HIV-infected patients treated with indinavir, the promoter polymorphism (UGT1A1*28) is of less significance than the coding region (UGT1A1*6) mutation as a risk factor for hyperbilirubinaemia. The Ki values determined for indinavir inhibition of UGT1A1 are consistent with an interaction in vivo, with an additive effect in patients with already impaired bilirubin glucuronidation activity.

[1]  J. Miners,et al.  Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. , 2006, British journal of clinical pharmacology.

[2]  Yoshiro Saito,et al.  RACIAL VARIABILITY IN HAPLOTYPE FREQUENCIES OF UGT1A1 AND GLUCURONIDATION ACTIVITY OF A NOVEL SINGLE NUCLEOTIDE POLYMORPHISM 686C> T (P229L) FOUND IN AN AFRICAN-AMERICAN , 2005, Drug Metabolism and Disposition.

[3]  M. Kaito,et al.  Genetic polymorphisms of bilirubin uridine diphosphate‐glucuronosyltransferase gene in Japanese patients with Crigler–Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects , 2004, Journal of gastroenterology and hepatology.

[4]  Kazuo Komamura,et al.  UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer , 2004, Clinical pharmacology and therapeutics.

[5]  A. Galetin,et al.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J. Miners,et al.  Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. , 2004, Annual review of pharmacology and toxicology.

[7]  D. Greenblatt,et al.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[8]  A. Galetin,et al.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[9]  K. Ruxrungtham,et al.  Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. , 2003, The Journal of antimicrobial chemotherapy.

[10]  Jos H Beijnen,et al.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs , 2002, AIDS.

[11]  J. Miners,et al.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.

[12]  M. Mori,et al.  Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. , 2002, Biochemical and biophysical research communications.

[13]  R. Green,et al.  Mechanism of indinavir-induced hyperbilirubinemia. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Ghosh,et al.  Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype , 2000, Human mutation.

[15]  A. Di Rienzo,et al.  Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. , 1999, Pharmacogenetics.

[16]  J. Potter,et al.  UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. , 1999, Pharmacogenetics.

[17]  K. Hayasaka,et al.  Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate‐glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese , 1998, Biochemistry and molecular biology international.

[18]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Yamamoto,et al.  Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. , 1998, Biochimica et biophysica acta.

[20]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[21]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[22]  P. Deutsch,et al.  Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[23]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[25]  J. Miners,et al.  Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. , 1988, Biochemical pharmacology.

[26]  P. Bosma.  Inherited disorders of bilirubin metabolism. , 2003, Journal of hepatology.

[27]  S. Yasumura,et al.  Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese , 1999, Journal of Human Genetics.

[28]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.